Author Archives: Marta Figueiredo PhD

Work Stops on Fezagepras, or PBI-4050, as Potential IPF Treatment

Liminal BioSciences is stopping the clinical development of its investigative oral therapy fezagepras (PBI-4050) for idiopathic pulmonary fibrosis (IPF), based on interim pharmacological data from a Phase 1 clinical trial testing it at ascending doses in healthy volunteers. The decision comes less than a month after the company announced plans…

Changes in Blood Cell Ratios Linked to Worse Outcomes

Idiopathic pulmonary fibrosis (IPF) patients showing greater changes in blood cell ratios often used as markers of inflammation are at higher risk of lung function decline, respiratory hospitalization, and death, according to a post-hoc analysis of data from several Phase 3 clinical trials. Notably, these associations were more pronounced…

Galapagos Advances GLPG4617 Into Phase 2 Trial

In a move that refocuses its clinical pipeline, Galapagos is discontinuing the development of GLPG1205, its experimental therapy for idiopathic pulmonary fibrosis (IPF), and advancing its most recent IPF candidate, GLPG4617, into a Phase 2 clinical trial. These and other decisions toward a “more risk-balanced pipeline” are…